1.	EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF103659, NCT00338247
2.	Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients Phase: Phase III, Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: GEICAM/2006-14, Nº EudraCT 2007-007031-13, NCT00841828
3.	Phase II/III Randomized Study of Lapatinib Ditosylate in Patients With HER1- and/or HER2-Overexpressing Stage IV Transitional Cell Carcinoma of the Bladder Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OCTG-LaMB, OCTG-LaMB, BL-2007-02, EUDRACT-2007-001826-28, EU-20929, NCT00949455
4.	Phase III Randomized Study of Letrozole With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage IV Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF30008, UCLA-0311034-01, NCT00073528
5.	ErbB2 Over-Expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF104383, NCT00272987
6.	Phase III Randomized Study of Fulvestrant With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage III or IV Hormone Receptor-Positive Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40302, NCT00390455
7.	Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: EGF102988, NCT00424255
8.	A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NSABP B-41, NCT00486668
9.	Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer Phase: Phase III Type: Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 104578, NCT00486954
10.	ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF106708, BIG 2-06/N063D/MAC13, NCT00490139
11.	Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG108838, NCT00558103
12.	A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer Phase: Phase III Type: Genetics, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GBG 44, EudraCT No.: 2006-005834-19, NCT00567554
13.	Phase III Randomized Study of Taxane-Based Chemotherapy in Combination With Lapatinib Ditosylate Versus Trastuzumab (Herceptin®) in Women With HER2/neu-Positive Metastatic Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-NCIC-MA31, MA31, GSK-EGF108919, EUDRACT-2007-004568-27, NCT00667251
14.	Phase III Randomized Study of Fulvestrant With or Without Lapatinib Tosylate and/or Aromatase Inhibitor Therapy in Postmenopausal Women With Metastatic Breast Cancer That Progressed After Prior Aromatase Inhibitor Therapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GIM-GIM8-OVER, GIM8-OVER, EUDRACT-2007-006031-30, EU-20853, GSK-GIM-GIM8-OVER, ZENECA-GIM-GIM8-OVER, OVER, NCT00688194
15.	LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF110656, EGF110656-TRIO-CIRG 013, NCT00680901
16.	Phase III Randomized Study of Neoadjuvant Paclitaxel in Combination With Trastuzumab (Herceptin®) and/or Lapatinib Ditosylate in Patients With HER2-Positive Resectable Stage II or III Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40601, CALGB 40601, NCT00770809
17.	Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3144A2-3003, NCT00777101
18.	An Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TDM4370g, 2008-005 713-22, NCT00829166
19.	Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111438, NCT00820222
20.	Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 112515, NCT00968968
21.	Phase I/II Randomized Study of Neoadjuvant Therapy Comprising Docetaxel and Lapatinib Ditosylate With or Without Fluorouracil, Epirubicin Hydrochloride, Cyclophosphamide (FEC Chemotherapy) Versus Docetaxel and Trastuzumab (Herceptin®) in Combination With FEC Chemotherapy in Women With HER2-Positive Locally Advanced, Inflammatory, or Large Resectable Breast Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-10054, GSK-EORTC-10054, EUDRACT-2006-000864-94, NCT00450892
22.	Phase I/II Randomized Pilot Study of Neoadjuvant Lapatinib Ditosylate in Women With Ductal Carcinoma In Situ of the Breast Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and over Sponsor: NCI Protocol IDs: MDA-P50-CA-58183, H-19895, BCM-H-19895, BCM-P50-CA-58183, NCT00555152
23.	Study Evaluating the Combination of Neratinib and Capecitabine in Solid Tumors and Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3144A1-2206, NCT00741260
24.	Study to Assess dHER2+AS15 Cancer Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GSK-dHER2AS15, NCT00952692
25.	Ketoconazole, Hydrocortisone, Dutasteride and Lapatanib (KHAD-L) in Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-374, NCT00953576